Tositumomab and Iodine I 131 Tositumomab
Hypersensitivity reactions, Anaphylaxis; Cyopenia
Hypersensitivity reactions, Anaphylaxis
- Medications for the treatment of such reactions should be available for immediate use.
- The majority of patients who receive this therapeutic regimen experience severe thrombocytopneia and neutropenia. Do not administer this regimen to patients with > 25% lymphoma marrow involvement and/or impaired bone marrow reverse
Pregnancy Category X
- This product contains a radioactive component and should be administered only by physicians and other health professionals qualified in training in the safe use and handling of radionuclides.
- Physicians must be in the process or have been certified by Corixa Corporation in dose calculation and administration of this product.
Patient Counseling Information
Updated January 2018